{
  "N/R/U": null,
  "Applicant": "Genentech, Inc.",
  "BLA Number": "761371",
  "Proprietary Name": "Ocrevus Zunovo",
  "Proper Name": "ocrelizumab and hyaluronidase-ocsq",
  "BLA Type": "351(a)",
  "Strength": "920MG/23ML; 23,000UNITS/23ML (40MG/1,000UNITS/ML)",
  "Dosage Form": "Injection ",
  "Route of Administration": "Subcutaneous",
  "Product Presentation": "Single-Dose Vial",
  "Marketing Status": "Rx",
  "Licensure": "Licensed",
  "Approval Date": "13-Sep-24",
  "Ref. Product Proper Name": null,
  "Ref. Product Proprietary Name": null,
  "Supplement Number": null,
  "Submission Type": "Original",
  "License Number": "1048",
  "Product Number": "1",
  "Center": "CDER",
  "Date of First Licensure": null,
  "Exclusivity Expiration Date": null,
  "First Interchangeable Exclusivity Exp. Date": null,
  "Ref. Product Exclusivity Exp. Date": null,
  "Orphan Exclusivity Exp. Date": null
}